DITTO Daily has raised £1.35m in pre-seed funding led by Eka Ventures
The investment will be used to help the startup scale its science-led supplements targeting menstrual symptoms.
The female-founded firm, which was founded in 2024, has grown a sizeable online community via social media with 116k followers on Instagram and TikTok.
DITTO is addressing a significant disconnect between menstrual health research and evidence-based solutions available to women.
Eka Ventures led the raise, with participation from notable investors including Jean-Baptise Wautier.
Founder Alice van der Schoot, an acclaimed nutrition scientist, developed the Cycle Supplement to comprehensively target both the mental and physical challenges of the menstrual cycle – addressing a significant unmet need.
She said: “For too long, there has been a huge disconnect between what science understands and the solutions available to those suffering from cycle-related symptoms.
“Too many are given outdated advice or left to navigate trial and error with ineffective approaches.
“At DITTO, we’re setting a new standard in how we understand and manage menstrual cycles through a science-led approach, ensuring women have access to the solutions they deserve.
“This funding allows us to accelerate our research and deliver more evidence-based solutions to the billions of women who need them.”
The supplement is formulated with 10 carefully selected ingredients with the strongest clinical evidence for menstrual cycle symptom relief.
It features an innovative nutrient delivery biotechnology, ‘beadlet-in-oil’, designed to enhance nutrient absorption.
Since launching in the UK four months ago, the supplement has seen significant uptake, particularly among those with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).
The Cycle Supplement has demonstrated strong clinical validation, with a recent clinical trial showing 88 per cent of participants experienced a reduction in overall symptom severity.
This is echoed by user reviews that consistently highlight its positive impact on menstrual cramps, mood swings, bloating, and energy levels.
Moving forward, DITTO has plans for three more clinical trials later this year.
Camilla Dolan, general partner at Eka Ventures, said: “Eka is thrilled to lead DITTO Daily’s pre-seed round, backing Alice’s vision to translate cutting-edge academic science into mainstream, efficacious products that improve women’s daily health from the inside.
“Early feedback and clinical results from DITTO Daily’s first product, Cycle supplement, demonstrates the unmet need in women’s health and the team’s ability to deliver fast, evidence-based impact.”